Avibactam Tomilopil Form 1: A Rare Pharmaceutical Mesophase

Avibactam tomilopil (AVT) is an orally available prodrug of the β-lactamase inhibitor avibactam that is in development for the treatment of antibiotic-resistant urinary tract infections. Initial solid-state characterization suggested a mixture of the crystalline and amorphous phases. However, subsequent attempts to obtain fully crystalline material were unsuccessful and resulted in comparable powder X-ray diffraction patterns containing both sharp peaks and broad areas consistent with diffuse scattering. Extensive solid form screening identified no additional forms of AVT, crystalline or otherwise. Likewise, cocrystal screening found no commercially viable hits, leaving Form 1 as the only viable solid form of AVT for clinical and commercial development. It therefore became imperative to fully understand the molecular level structure of the solid. Through extensive experimental and computational analysis, it was discovered that AVT Form 1 is a thermotropic mesophase─a state of matter infrequently encountered in pharmaceuticals.

Authors

Institutions

Publication Details

Journal
Crystal Growth & Design
Published
2025-09-25
DOI
https://doi.org/10.1021/acs.cgd.5c00904
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Avibactam Tomilopil Form 1: A Rare Pharmaceutical Mesophase

Marissa Puzan, Brian Samas, Erika L. Buckle, Michael A. Bellucci et al.
Crystal Growth & Design
Drug Solubulity and Delivery Systems
article

Avibactam Tomilopil Form 1: A Rare Pharmaceutical Mesophase

Marissa Puzan, Brian Samas, Erika L. Buckle, Michael A. Bellucci, Alpana Ankush Thorat, Zhuocen Yang, Kevin DeBoyace, Maryam S. Sadeghi, Geoffrey P. F. Wood, Jaypee Quino, Guangxu Sun, Kyla Suszynski
article en

Abstract

Avibactam tomilopil (AVT) is an orally available prodrug of the β-lactamase inhibitor avibactam that is in development for the treatment of antibiotic-resistant urinary tract infections. Initial solid-state characterization suggested a mixture of the crystalline and amorphous phases. However, subsequent attempts to obtain fully crystalline material were unsuccessful and resulted in comparable powder X-ray diffraction patterns containing both sharp peaks and broad areas consistent with diffuse scattering. Extensive solid form screening identified no additional forms of AVT, crystalline or otherwise. Likewise, cocrystal screening found no commercially viable hits, leaving Form 1 as the only viable solid form of AVT for clinical and commercial development. It therefore became imperative to fully understand the molecular level structure of the solid. Through extensive experimental and computational analysis, it was discovered that AVT Form 1 is a thermotropic mesophase─a state of matter infrequently encountered in pharmaceuticals.

Crystal Growth & DesignVol. 25(20)
Pfizer (United States) (US), Shenzhen Weiguang Biological Products (China) (CN), Vi Technology (United States) (US), Cambridge Electronics (United States) (US)
Openalex Percentile: Top 80%
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Avibactam Tomilopil Form 1: A Rare Pharmaceutical Mesophase — Marissa Puzan, Brian Samas, et al. · Crystal Growth & Design (2025) | TGRS Research Map | TGRS